AIM
LPCN icon

Advantage Investment Management’s Lipocine LPCN Stock Holding History

Advantage Investment Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-85
Closed -$5K – 1031
2017
Q4 		$5K Hold
85
– – ﹤0.01% 825
2017
Q3 		$6K Hold
85
– – ﹤0.01% 792
2017
Q2 		$6K Hold
85
– – ﹤0.01% 807
2017
Q1 		$6K Hold
85
– – ﹤0.01% 784
2016
Q4 		$5K Hold
85
– – ﹤0.01% 751
2016
Q3 		$6K Hold
85
– – ﹤0.01% 707
2016
Q2 		$4K Hold
85
– – ﹤0.01% 729
2016
Q1 		$15K Hold
85
– – 0.01% 503
2015
Q4 		$19K Hold
85
– – 0.01% 479
2015
Q3 		$17K Hold
85
– – 0.01% 475
2015
Q2 		$12K Hold
85
– – 0.01% 554
2015
Q1 		$10K Hold
85
– – 0.01% 588
2014
Q4 		$8K Buy
+85
New +$7.18K 0.01% 557

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Advantage Investment Management's LPCN Position: Q1 2018 in Review

Advantage Investment Management sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 85 shares — an estimated $5K sold.

Advantage Investment Management first reported a position in LPCN in Q4 2014 and held it in 13 quarters. The position peaked at $19K in Q4 2015. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

  • Advantage Investment Management reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
  • Advantage Investment Management sold 85 Lipocine shares in Q1 2018, an estimated $5K.
  • Advantage Investment Management first reported a position in Lipocine in Q4 2014 and held it in 13 quarters.
  • Advantage Investment Management's Lipocine position peaked at $19K in Q4 2015.
  • 27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on Advantage Investment Management's 13F filing for Q1 2018, filed 15 May 2018.